EcoDrugPlus

Retinoic Acid Receptor Beta

Ensembl ID : ENSOKIG00005019445
Gene Symbol: RARB
1 Cross references
384 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSOKIG00005004510
Gene Symbol: RARB
3 Cross references
390 Possible Orthologues:

Retinoic Acid Receptor Beta-Like

Ensembl ID : ENSOKIG00005027858
Gene Symbol: LOC109909033
2 Cross references
374 Possible Orthologues:

Retinoic Acid Receptor Beta-Like

Ensembl ID : ENSOKIG00005026775
Gene Symbol: LOC109902077
2 Cross references
374 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSOKIG00005011518
Gene Symbol: RARG
3 Cross references
345 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSOKIG00005031812
Gene Symbol: RARG
3 Cross references
344 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSOKIG00005003174
Gene Symbol: RARG
3 Cross references
372 Possible Orthologues:

Retinoic Acid Receptor Gamma-A-Like

Ensembl ID : ENSOKIG00005029409
Gene Symbol: LOC109875941
2 Cross references
325 Possible Orthologues:

Retinoid X Receptor Alpha

Ensembl ID : ENSOKIG00005001820
Gene Symbol: RXRA
2 Cross references
175 Possible Orthologues:

Retinoid X Receptor Beta

Ensembl ID : ENSOKIG00005036437
Gene Symbol: RXRB
3 Cross references
199 Possible Orthologues:

Rho-Associated Protein Kinase 1

Ensembl ID : ENSOKIG00005029665
Gene Symbol: LOC109871603
3 Cross references
207 Possible Orthologues:

Rho-Associated Protein Kinase 2-Like

Ensembl ID : ENSOKIG00005006313
Gene Symbol: LOC109904161
3 Cross references
219 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).